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SYNOPSIS
The thesis entitled “Application of the sulfinyl group as a pendant nucleophile in the formal synthesis of (+)-solamin and toward the synthesis of (-)-mucocin” consists of three chapters.
CHAPTER I

Synthesis and applications of enantiommerically enriched sulfoxides in organic synthesis.
This section deals with the preparation of homochiral sulfoxides and the application of the sulfinyl chirality to asymmetric synthesis of bioactive target molecules as reported by various research groups.
CHAPTER II

A formal convergent synthesis of (+)-solamin

           In this chapter a brief account of the synthesis of (+)-solamin reported by various research groups and an elaborate account of the present work is described.
             Solamin is a mono tetrahydrofuran (THF) acetogenin isolated from the seeds of Annona muricata (Annonaceae) along with five other mono THF acetogenins. Acetogenins are a class of compounds that have been isolated from several genera of the plant family Annonaceae. Acetogenins are fairly large molecules, which are characterized by two functional units, the hydroxylated tetrahydrofuran (THF) and the -unsaturated lactone ring, separated by a long alkyl chain. Mccloud et al. reported annonacin as the first annonaceous acetogenin containing a single THF ring. Several other mono tetrahydrofuran acetogenins such as annonacinone, corrosolin, corrosolone, murisolin and solamin have subsequently been isolated. All the reported compounds of this class possess the same basic carbon skeleton, Figure-1. The acetogenins have emerged as a new class of cytotoxic compounds and they are under evaluation as potential anti-cancer agents. Many of these acetogenins have very potent and diverse biological effects such as cytotoxic, anti-tumor, anti-malarial, pesticidal and anti-feedant activities. All the acetogenins were significantly toxic to the two cell lines, from 1 to 10-2 g  ml-1 for VERO and 3 x 10-1 to 10-4 g ml-1 for KB cells.1 Generally mono THF acetogenins are more toxic to KB than VERO cells. The action of the acetogenins in multiple drug resistant cells, mediated by an intracellular glycoprotein pump suggests a possible extracellular action on cell membranes
Figure-1

The retrosynthetic analysis of solamin is depicted in Scheme-1. Solamin 1 was envisioned to be synthesized by alkylation of thio lactone 3 with iodo alkane 2. The iodo compound 2 was envisaged to  be obtained from  the tetrol derivative  4  by a Williamson type reaction. Compound 4 in turn can be obtained by the alkylation of the β-keto sulfoxide 6 with the iodo acetonide 5 and forming C17-C18 bond. The iodo acetonide 5 was envisioned to be obtained by a Pummerer followed by ene reaction from bromo acetonide 7 which inturn can be traced to β-hydroxy sulfoxide 8. The β-keto sulfoxide 6 was similarly traced to β-hydroxy sulfoxide 9 . The β-hydroxy sulfoxides 8 and 9 were envisaged to be readily obtained from      (R)–methyl-p-tolyl sulfoxide. The synthesis of solamin was taken up to showcase the utility of a methodology demonstrating the nucleophilic potential of an inramolecular sulfinyl group to functionalize activated by N-bromosuccinimide to prepare bromohydrins regio and stereoselectively.                                                   


Scheme-1



The key step in the proposed route was the alkylation reaction between the iodide 5 and the β-keto sulfoxide 6 to construct the C17-C18 bond of solamin. Efforts were devoted to identify the optimum conditions using racemic model substrates. The synthesis of racemic iodo compound  16 commenced wih the addition of the lithio anion of racemic methyl p-tolyl-sulfoxide 11  to acrolein 12 to afford an equimolar inseperable mixture of β-hydroxy sulfoxides 13. (For clarity only one of the diastereomer is depicted). Treatment of 13 with a slight excess of  N-iodosuccinimide and H2O in toluene afforded the iodohydrin 14 . Acetylation the iodohydrin 14 using Ac2O and Et3N at room temperature furnished acetate 15. Reduction of sulfoxide to sulfide was carried out using TFAA and NaI in acetone at  0 oC  to yield  iodo sulfide 16. The other partner 18 for the model study was prepared by  treating the lithio anion of 11 with the benzyl ether of (S)-ethyl lactate, Scheme-2.
Scheme-2

Reagents and conditions: a) LDA, THF, 0 oC, 10 min then cooled to -40 oC added 11 30 min, cooled to -78 oC then added 12, 10 min, 80%; b) 1.5 eq NIS, 2 eq H2O, toluene, rt, 30 min, 60%; c) Ac2O, Et3N, DCM, 0 oC to rt, 80%; d) TFAA, NaI, acetone, 0 oC to rt, 70%; e) LDA, THF, 0 oC, 10 min then cooled to -40 oC added 11, 30 min then 17 at 0 oC, 60%; f) m-CPBA, DCM, 0 oC, 10 min, 90%.

The alkylation of 18 with iodo compound 16 was explored under a variety of conditions. Alkylation employing DBU, K2CO3, Cs2CO3 and LDA as bases returned only unreacted starting material. The alkylation was next attempted on the β-keto sulfone 19 obtained by oxidation of 18. Attempted alkylation of 19 with 16 using various bases led to elimination of the acetate group to furnish compound 20, Scheme-3.


Scheme-3

To circumvent the problem of acetate elimination alkylation was attempted on iodo acetonide 21 readily obtained from iodo diol 14. The compound 14 was  treated with 2,2’-DMP in DCM in the presence of catalytic amount of CSA to afford the corresponding acetonide, that on reduction  using  TFAA and NaI in acetone at 0 oC furnished the sulfide acetonide 21. Alkylation of the anoin derived from 19 with 21 did not afford the desired product, a less polar product was isolated and was found to be the allyl alcohol 22, Scheme-4.
A revised synthetic strategy was devised to construct the C17-C18 bond of solamin employing the Wittig –Horner reaction, Scheme-5.

Revised strategy
In the revised strategy, compound 2 was envisaged to be obtained from the enone 37 which in turn was envisioned to be obtained by coupling aldehyde 30 with phosponate 36. The aldehyde 30 can be prepared from bromo acetonide 9 . The phosponate 36 was traced to the oxazolidinone derivative 32 which in turn was to be obtained starting from acid 31, Scheme-5.
Scheme-4


Scheme-5

The synthesis commenced with the addition of the lithio anion of (R)-methyl-p-tolyl sulfoxide 10 to acryloyl imidazole 28 to furnish keto sulfoxide 29. Stereoselective reduction of the ketone to an allyl alcohol using Dibal-H at -78 oC furnished compound 8.Treatment of 8 with a slight excess of freshly recrystallised NBS and water in toluene afforded the bromohydrin 30 which was converted to the corresponding acetonide 7. The acetonide 7 was subjected to Pumerer reaction in the presence of TFAA to afford the intermediate which without isolation on treatment with 1-undecene and SnCl4 furnished the ene product 5. The bromine  in 5 was replaced with the hydroxy group using NaNO2 in DMF at 80 oC to furnish 31. Swern oxidation of the carbinol 31 afforded aldehyde  32, Scheme-6.
Scheme-6

Reagents and conditions: a) LDA, THF, 0 oC, 10 min, 10, -40 oC, 30 min cooled to -78 oC, 28, 30 min 65%; b) Dibal-H, THF, -78 oC, 1h, 75%; c) NBS, H2O, Toluene, rt, 3h, 70%; d) 2,2 DMP, DCM, cat CSA, rt, 4h, 90%; e) TFAA, DCM, 0 oC, 30 min, 1-undecene, SnCl4, 30 min, 60%; f) NaNO2, DMF, 80 oC, 8h, 80%; g) (COCl)2, DMSO, DCM, Et3N, -78 oC,  45 min, 90%. 


The synthesis of the phosponate fragment commenced from the acid 27. Treatment of the oxazolidinone with the mixed anhydride obtained by treatment of acid 27 with pivaloylchloride in DCM/Et3N followed by addition of LiCl  furnished the imide 26. Hydroxylation of the imide using Davis’ reagent and NaHMDS as the base at -78 oC provided the alcohol 33.  Cleavage of the auxillary using   methoxymagnesium bromide yielded  the hydroxy ester 34 which was further protected as its Mom-ether 35. Coupling  of the ester 35 with the anion derived from dimethyl phosponate using n-BuLi at -78 oC afforded the keto phosponate 25, Scheme-7.
Scheme-7

 Reagents and conditions: a) Pivaloyl chloride, DCM, Et3N, 0 oC then oxazolidinone, LiCl, rt, 8h, 90%;  b) NaHMDS, THF, -78 oC, Davis reagent, 15 min, 82%;  c) MeOMgBr, DCM, MeOH, 0 oC, 10 min, 80%; d) MOM-Cl, DCM, Et3N, 0 oC to rt, 10h, 90%;  e) Methyl dimethyl phosponate, n-BuLi, THF, -78 oC, 1h, 75%.

The coupling of the aldehyde 32 and the phosponate 25 was achieved using Ba(OH)2 as the base at room temperature to furnish enone 23. Stereoselective reduction of the enone using Zn(BH4)2 furnished the allyl alcohol 36 (de > 98%). Treatment of the  allylic alcohol 36 with Raney-nickel in a hydrogen atmosphere led to reduction of double bonds and hydrogenolysis of the carbon-sulfur bond. The hydroxyl group was converted to mesylate using methane sulfonyl chloride and Et3N to afford compound 37. Attempted deprotection of the acetonide using aq 70% AcOH to diol instead furnished the cyclized product 38 with concomitant deprotection of the Mom group.

The diol THF derivative 38 was subjected to reaction with TBS-Triflate to afford the diTBS derivative 39 that upon treatment with Pd/C under H2 pressure delivered the debenzylated alcohol 40. This alcohol was converted into the iodo derivative 2, Scheme-8. The compound 2 has been employed as the key intermediate in the synthesis of solamin by Mioskowski and co-workers. Thus a formal synthesis of trans-Solamin was completed.

Scheme-8 
Reagents and conditions: a) Ba(OH)2, aq. THF, rt, 30 min, 70%, b) Zn(BH4)2, THF, -40 oC, 2h, 85%, c) i) Ra-Ni/ EtOH, H2, rt, 2h, 65% ii) Mesyl chloride, DCM, Et3N, 0 oC, 10 min, 100%, d) Aq. 70% AcOH, 80 oC, 4h, 65%, e) TBSOTf, DCM, 2,6-Lutidine, 0 oC, 30 min, 95% f) Pd/C, H2, EtOAc, rt, 6h, 95% g) TPP/I2, Imidazole, THF, 0 oC, 30 min, 71%.




Chapter III
Toward the synthesis of (-)–mucocin.
             In this chapter a brief account of the synthesis of (-)-Mucocin reported by various research groups and an elaborate account of the present work is described. (-)-Mucocin 43, an annonaceous acetogenin, was isolated by McLaughlin and co-workers from the leaves of Rollinia mucosa. Mucocin was the first acetogenin shown to posses tetrahydropyran ring (THP) along with a THF ring. Mucocin shows selective inhibition against A-549 (lung cancer) and PACA-2 (pancreatic cancer) solid tomor cell lines with a potency 10,000 greater than the known antitumor agent adriamycin. The mode of action is through blockage of the mitochondrial complex I (NADH-ubiquinone oxidoreductase) and inhibition of the plasma membrane NADH oxidase resulting in ATP depletion and consequent apoptosis in malignant cells.



The retrosynthetic approach of (-)-mucocin was depicted in Scheme-9. Mucocin 41 was envisaged to be synthesized  from the pyran fragment 42 and the iodo compound 43 employing the boron-alkyl Suzuki reaction to construct the C13-C14 bond. The pyran compound 42 can be obtained from the triene 44 which in turn was envisioned to be obtained by a regioselective opening of epoxy tosylate 48 by diol 47. The vinyl iodide 43 was planned to be synthesized from diol 45 and lactone 3. The diol 45 was envisaged to be obtained from aldehyde 46 using proline 
Scheme-9 
. 
catalysed α-hydroxylation reaction. The  C13-C22 chain of mucocin posseses a C2 symmetry and a bidirectional approach to this fragment was envisioned. The diol fragment 47 was planned to to be prepared from the dibromo compound 49, which in turn can be obtained from the keto sulfoxide 50 that in turn can be obtained from diene diester 52 and (S)-methyl-p-tolyl sulfoxide 51.
The synthesis commenced with the addition of the lithio anion of sulfoxide 51 with diester  52 to furnish the diketo compound 50. The diketo compound 50 on diastereoselective reduction using Dibal-H in the presence of anhydrous ZnCl2  afforded the diol 54 which was too polar and water soluble to isolate from aqueous solution, Scheme-10
Scheme-10
In a revised strategy, Scheme-11, the diene tetrol derivative 47 was envisioned to be obtained via compound 49 from bromohydrin 55. Bromohydrin 55 was envisioned to be obtained from  β-keto sulfoxide 56 which in turn can be obtained from ethyl sorbate 57 and (S)-methyl-p-tolyl sulfoxide 51.
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The revised synthesis of tetrol derivative 47 following the revised strategy commenced with the addition of lithio anion of sulfoxide 51 to ethyl sorbate 57 to afford the keto sulfoxide 56. Diastereoselective reduction of the keto carbonyl using Dibal-H in the presence of anhydrous ZnCl2 utilizing the sulfinyl group as the auxillary furnished the dienol 58. The hydroxy group was protected as its silyl ether 59 using TBS-Cl and imidazole. Treatment of  59  with freshly recrystallised NBS (0.95 eq) and water in toluene afforded the bromohydrin 55. Cross metathesis of 55 using Grubbs’ 2nd generation catalyst yielded the dimer 60 in only 50% yield. The yield was significantly improved using Hoveyda-Grubbs catalyst and longer reaction periods to furnish compound 60 in 95% yield. The double bond was reduced using Adam’s catalyst to furnish 49 which was converted to the sulfone 61 using m-CPBA. The sulfone 61 was protected as the dibenzyl ether 62 using benzyl imidate and cat TfOH. The benzyl ether on treatment with an excess of TBAF delivered the allylic alcohol 63 which was desulfonylated using Mg-Hg in ethanol to yield the C2-symmetric diol 47 Scheme-12.

Scheme-12

Reagents and conditions: (a) LDA,THF, -40 oC, 54, 30 min, warm to 0 oC, 60, 52%; b) Dibal-H, ZnCl2,THF, -78 oC, 1h, 82%; c) TBS-Cl, Imidazole, DCM,  0 oC to rt, 8h, 90%; d) NBS, H2O, toluene, rt, 2h, 76%; e)  3 mol% Hoveyda-Grubbs catalyst DCM, reflux, 3 days 95%; f) PtO2, H2, 10 bar, MeOH:PhH (1:1) rt, 12h, 80%; g) mCPBA, DCM, 0 oC to rt, 30 min, 80%; h) Cl3CC=(NH)OBn, cat TfOH, DCM/Cyclohexane, 0 oC to rt, 2h, 70%; i) TBAF, THF,  0 oC to rt, 30 min,  72%; j) Mg, cat HgCl2, EtOH, 0 oC to rt, 2h, 70%.




The synthesis of the epoxy tosylate 48 commenced with the Wittig olefination of the commercially available aldehyde 64 to give the ester 65 which upon alane reduction delivered the allyl alcohol 66. Sharpless asymmetric epoxidation of 66 using (-)-DET furnished the epoxide 67 that upon reaction with tosyl chloride afforded the epoxy tosyltate 48, Scheme-13
Scheme-13


The coupling of the two fragments 47 and 48 was achieved  utilizing  a slightly modified protocol designed by Hoffman in the presence of BF3.Et2O to furnish tosylate 68. Treatment of 68 with K2CO3 in CH3CN and EtOH furnished the epoxide 69. One carbon homologation was performed following Falck’s protocol using trimethyl sulfonium iodide and n-BuLi to afford the allylic alcohol 70. The triene 70 was exposed to Grubbs’ 2nd generation catalyst in refluxing DCM to afford the six membered RCM product 71 and the eight membered RCM product 72 in equal amounts. The structure of these compounds were confirmed by NOESY studies. To improve the formation of 6-membered compound the hydroxy group in 69 was protected as the TES ether 73. This compound was reacted with Me3SI/n-BuLi to afford the triene 74 which was refluxed with Grubbs’ 2nd generation catalyst to yield the pyran 42 as the sole product. Thus the synthesis of C13-C34 fragment of (-)-mucocin was completed, Scheme-14.

Scheme-14 
Reagents and conditions: a) BF3.Et2O, DCM, 0 oC to rt, 15h, 70%; b) K2CO3, EtOH/ AcCN (1:1), rt, 12h, 90%; c) Me3SI, n-BuLi, THF, 0 oC to rt, 1h, 70%; d) 5 mol% Grubbs catalyst IInd generation catalyst, DCM, reflux, 12h, 80%; e) TES-Cl, DCM, Imidazole, 0 oC to rt, 2h, 90%.
The synthesis of the right hand side fragment commenced with the THP ether of propargyl alcohol 75. Alkylation of 75 with octyl iodide 76 using n-BuLi as the base in THF and HMPA as an additive at 0 oC afforded 77. Deprotection of the  THP group in 77 using catalytic CSA in MeOH afforded 78. Isomerisation of 78 to the terminal alkyne using Zipper reaction furnished the alkynol 79. Swern oxidation of 79 yielded the aldehyde 46. 

This aldehyde was subjected to the proline catalysed α-aminoxylation using nitrosobenzene in DMSO followed by insitu reduction with sodium borohydride to yield the aminoxy derivative that was reduced to diol 45 using copper sulfate and MeOH. The diol was alkylated with the lactone 3 using a three step sequence. Initially the primary hydroxy group of the diol was converted to triflate using Tf2O in the presence of 2,6-lutidine and the secondary hydroxy group was converted into the silyl ether using TBS-triflate. This triflate was treated with the enolate generated from 48 using LHMDS at -78 oC to furnish the alkylated product 80. The sulfide group in 80 was converted to the sulfoxide using m-CPBA follwed by thermal elimination to afford the unsaturated lactone 81. The alkyne was converted to the bromo alkyne 82 by treatment with NBS and AgNO3 in acetone. The bromo compound 82 was converted into the vinyl stannane using palladium(0) catalyzed reaction with tributyltin hydride. The vinyl stannane without isolation was directly transformed to vinyl iodide 43 by reaction with iodine. The fragment 43 corresponds to C1-C12 subunit of mucocin, Scheme-15.








Scheme-15
 Reagents and conditions: a) n-BuLi, THF, HMPA, -15 oC to rt, 1h, 65% b) 5 mol% CSA, MeOH, rt, 8h, 90%; c)1,3 Diaminopropane, NAH, 70 oC, 4h, 70%, d) (COCl)2, DMSO, DCM, Et3N, -78 oC, 45 min, 85%; e) i) 20 mol% L-Proline, PhNO, DMSO, rt, 1h; ii) CuSO4, MeOH, rt, 8h, 70% (two steps);  f) Tf2O, DCM, 2,6-lutidine, -78 oC, 10 min then TBSOTf, -78oC to  0 oC, 20 min then added to 48 in LHMDS, THF, HMPA, -78 oC, 30 min, 70%; g) i) m-CPBA/ DCM, 0 oC, 2h; ii) Toluene 80 oC, 6h, 80% (two steps); h) NBS, AgNO3, acetone 0 oC to rt, 1h, 75%; i) Bu3SnH, THF, Pd Cl2 (PPh3)2  0 oC, 1h, I2/ DCM -78 oC, 10 min 70%. 
	
Attempted efforts to couple the trialkyl borane derived from pyran fragment 42 with the vinyl iodide 43 using B-alkyl suzuki reaction using 9-BBN dimer,  PdCl2(dppf)2  and aq.Cs2CO3 as the base were unsuccessful and did not yield the desired product. Efforts are currently in progress to complete the synthesis of (-)-mucocin.






















































